Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
WuXi STA opens a new large scale continuous manufacturing plant
Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
Subscribe To Our Newsletter & Stay Updated